ABSTRACT
Objective To study and analyze the clinical efficacy of compound preparation Femoston for the treatment of perimenopausal syndrome in women. Methods 60 women with perimenopausal syndrome from April 2016 to July 2017 were selected and randomly divided into the control group and the experimental group, 30 cases for each group. The control group was given estradiol valerate tablets, and the experimental group was treated with compound preparation Femoston, one tablet a day. The treatment time of the two groups was 6 months, and the clinical efficacy of the experimental group and the control group were compared and analyzed. Results After the corresponding treatment, 4 patients were ineffective in the experimental group. In the control group, 7 patients were ineffective, 10 cases were effective, and 13 cases were good effective. The effective rate of the experimental group was 86.67%, which was significantly higher than that (76.67%) of the control group with statistical significance (P<0.05). The level of FSH in the experimental group was (24.10 ± 15.24) U/L, which was significantly better than that of the control group (42.72 ±15.56) U/L with statistical significance (P<0.05). There were no obvious adverse reactions in the two groups, and the rate of adverse reactions such as vomiting, abdominal pain and breast pain were 3.33% and 6.67%, respectively, and there was no statistical significance. Conclusion The clinical efficacy of compound preparation Femoston for treating perimenopausal syndrome is ideal. Femoston could significantly improve the hormone levels in patients with high safety.
ABSTRACT
Objective To study and analyze the clinical efficacy of compound preparation Femoston for the treatment of perimenopausal syndrome in women. Methods 60 women with perimenopausal syndrome from April 2016 to July 2017 were selected and randomly divided into the control group and the experimental group, 30 cases for each group. The control group was given estradiol valerate tablets, and the experimental group was treated with compound preparation Femoston, one tablet a day. The treatment time of the two groups was 6 months, and the clinical efficacy of the experimental group and the control group were compared and analyzed. Results After the corresponding treatment, 4 patients were ineffective in the experimental group. In the control group, 7 patients were ineffective, 10 cases were effective, and 13 cases were good effective. The effective rate of the experimental group was 86.67%, which was significantly higher than that (76.67%) of the control group with statistical significance (P<0.05). The level of FSH in the experimental group was (24.10 ± 15.24) U/L, which was significantly better than that of the control group (42.72 ±15.56) U/L with statistical significance (P<0.05). There were no obvious adverse reactions in the two groups, and the rate of adverse reactions such as vomiting, abdominal pain and breast pain were 3.33% and 6.67%, respectively, and there was no statistical significance. Conclusion The clinical efficacy of compound preparation Femoston for treating perimenopausal syndrome is ideal. Femoston could significantly improve the hormone levels in patients with high safety.